
Amazon has asked India’s Supreme Court to pause an expedited review of allegations that the US firm concealed information while seeking antitrust clearance for a 2019 deal with India’s Future Group, legal papers seen by Reuters showed.
The Competition Commission of India (CCI) in June accused Amazon of concealing facts and making false submissions when it sought approval for the $200 million investment into a Future unit in 2019, a deal that is now at the heart of protracted legal disputes between the two sides.
Amazon told Reuters at the time that it was confident of addressing the watchdog’s concerns. The Supreme Court approach by Amazon comes as the CCI on Wednesday held a closed-door hearing where the US firm’s lawyers declined to argue and explain their position on the matter, saying they had asked the top court to pause the process.
Related: India’s Future Files New Antitrust Case Against Amazon
The watchdog noted in an internal document – seen by Reuters – that it had decided to give no extensions to the company to explain its position and will now issue an order in due course.
The CCI decision is critical to Amazon’s legal challenges. If the CCI rules against Amazon and revokes the 2019 approval, it could have wide-ranging ramifications on the US firm’s ongoing legal battle with Future, people familiar with the case say.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas